Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease.
Although sulfasalazine, a 5-aminosalicylic acid (5-ASA) agent, is still the anti-inflammatory agent of choice for ulcerative colitis and Crohn's disease, newer formulations, which release drug to specific regions of the colon for maximal efficacy, also can be appropriate first-line agents. This article reviews recent clinical studies of therapy with older and newer 5-ASA formulations.
Brzezinski
A
A
Department of Gastroenterology, Cleveland Clinic Foundation, OH 44195, USA.
Rankin
G B
GB
Seidner
D L
DL
Lashner
B A
BA
D000284:Administration, Oral; D000636:Aminosalicylic Acids / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001391:Azo Compounds / Q000627:therapeutic use; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D006801:Humans; D006863:Hydrogen-Ion Concentration; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D019804:Mesalamine
D000636:Aminosalicylic Acids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001391:Azo Compounds; D003692:Delayed-Action Preparations; D019804:Mesalamine